See more : China Oriental Group Company Limited (CUGCF) Income Statement Analysis – Financial Results
Complete financial analysis of Champions Oncology, Inc. (CSBR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Champions Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Seach Medical Group Ltd (SEMG.TA) Income Statement Analysis – Financial Results
- JPMorgan US Smaller Companies Investment Trust plc (JUSC.L) Income Statement Analysis – Financial Results
- Nihon Seimitsu Co., Ltd. (7771.T) Income Statement Analysis – Financial Results
- Innovation Pharmaceuticals Inc. (IPIX) Income Statement Analysis – Financial Results
- blueharbor bank (BLHK) Income Statement Analysis – Financial Results
Champions Oncology, Inc. (CSBR)
About Champions Oncology, Inc.
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.16M | 53.87M | 49.11M | 41.04M | 32.12M | 27.07M | 20.24M | 15.41M | 11.18M | 8.86M | 11.55M | 8.27M | 7.15M | 6.88M | 4.89M | 3.71M | 1.40M | 0.00 | 0.00 | 1.80M | 2.00M | 2.01M | 2.13M | 2.21M | 2.18M | 2.20M | 2.33M | 2.16M | 2.14M |
| Cost of Revenue | 29.40M | 29.53M | 23.63M | 21.47M | 16.88M | 14.27M | 10.55M | 9.70M | 8.69M | 7.63M | 6.26M | 5.32M | 4.90M | 3.14M | 1.98M | 1.98M | 0.00 | 0.00 | 0.00 | 553.90K | 601.40K | 501.87K | 595.29K | 639.71K | 1.79M | 1.17M | 1.21M | 1.04M | 1.06M |
| Gross Profit | 20.75M | 24.34M | 25.48M | 19.57M | 15.24M | 12.80M | 9.69M | 5.71M | 2.50M | 1.23M | 5.29M | 2.95M | 2.25M | 3.74M | 2.91M | 1.73M | 1.40M | 0.00 | 0.00 | 1.24M | 1.40M | 1.50M | 1.53M | 1.57M | 389.29K | 1.03M | 1.12M | 1.12M | 1.08M |
| Gross Profit Ratio | 41.38% | 45.18% | 51.88% | 47.68% | 47.45% | 47.30% | 47.86% | 37.04% | 22.32% | 13.88% | 45.77% | 35.66% | 31.47% | 54.34% | 59.55% | 46.63% | 100.00% | 0.00% | 0.00% | 69.18% | 69.92% | 74.99% | 72.03% | 71.06% | 17.89% | 46.82% | 48.07% | 51.85% | 50.47% |
| Research & Development | 9.54M | 11.55M | 9.37M | 7.20M | 5.85M | 4.80M | 4.40M | 4.29M | 4.19M | 4.85M | 2.27M | 1.92M | 2.94M | 2.95M | 2.70M | 1.72M | 199.74K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.07M | 10.24M | 9.12M | 6.51M | 6.61M | 4.68M | 4.07M | 4.96M | 5.17M | 5.34M | 6.13M | 4.71M | 5.45M | 4.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 277.49K | 0.00 | 0.00 | 0.00 | 0.00 | 950.00K | 1.00M | 990.00K | 960.00K |
| Selling & Marketing | 7.06M | 7.00M | 6.38M | 5.52M | 4.24M | 3.06M | 2.57M | 3.26M | 3.45M | 4.28M | 3.16M | 2.67M | 2.93M | 1.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.13M | 17.24M | 15.50M | 12.03M | 10.86M | 7.73M | 6.64M | 8.22M | 8.62M | 9.62M | 9.28M | 7.38M | 8.38M | 6.02M | 3.15M | 2.06M | 1.19M | 170.06K | 144.12K | 1.44M | 1.46M | 1.60M | 1.60M | 1.69M | 322.48K | 950.00K | 1.00M | 990.00K | 960.00K |
| Other Expenses | 435.00K | -11.00K | -24.00K | 71.00K | -42.00K | -39.00K | -88.00K | -56.00K | -38.00K | 225.00K | -1.13M | -99.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.42K | 48.42K | 48.47K | 80.25K | 351.98K | 51.79K | 60.00K | 50.00K | 60.00K | 70.00K |
| Operating Expenses | 28.11M | 28.79M | 24.87M | 19.23M | 16.71M | 12.53M | 11.04M | 12.52M | 12.81M | 14.47M | 11.55M | 9.30M | 11.32M | 8.98M | 5.84M | 3.78M | 1.39M | 170.06K | 144.12K | 1.49M | 1.51M | 1.65M | 1.68M | 2.04M | 374.27K | 1.01M | 1.05M | 1.05M | 1.03M |
| Cost & Expenses | 57.51M | 58.32M | 48.50M | 40.70M | 33.59M | 26.80M | 21.60M | 22.22M | 21.50M | 22.10M | 17.81M | 14.61M | 16.21M | 12.12M | 7.82M | 5.76M | 1.39M | 170.06K | 144.12K | 2.04M | 2.11M | 2.15M | 2.28M | 2.68M | 2.16M | 2.18M | 2.26M | 2.09M | 2.09M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | 88.00K | 29.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 24.00K | 0.00 | 0.00 | 39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | 88.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.87M | 3.20M | 2.41M | 1.58M | 1.23M | 606.00K | 360.00K | 168.00K | 156.00K | 214.00K | 213.00K | 203.00K | 105.00K | 42.00K | 32.00K | 4.00K | 170.13K | 11.05K | 0.00 | 48.42K | 48.42K | 48.42K | 48.42K | 56.37K | 51.79K | 60.00K | 60.00K | 50.00K | 70.00K |
| EBITDA | -5.05M | -2.07M | 2.23M | 366.00K | -735.00K | 876.00K | -994.00K | -6.64M | -10.16M | -13.02M | -6.05M | -6.02M | -9.07M | -5.24M | -2.89M | -2.23M | -440.00K | -159.01K | -144.12K | -105.48K | -59.27K | -97.58K | -98.89K | -412.57K | 66.82K | 80.00K | 430.00K | 120.00K | 120.00K |
| EBITDA Ratio | -10.08% | -2.59% | 4.55% | 3.71% | -0.96% | 3.24% | -4.91% | -43.09% | -90.86% | -146.95% | -52.35% | -74.35% | -130.96% | -96.44% | -59.19% | -47.39% | 12.62% | 0.00% | 0.00% | -11.56% | -2.96% | -5.39% | -2.86% | -5.80% | 2.22% | 3.64% | 18.45% | 5.56% | 5.61% |
| Operating Income | -7.36M | -4.45M | 607.00K | 338.00K | -1.47M | 270.00K | -1.35M | -6.81M | -10.32M | -13.24M | -6.26M | -6.35M | -9.07M | -5.24M | -2.93M | -2.33M | 6.59K | -170.06K | -144.12K | -246.54K | -107.69K | -145.99K | -147.31K | -468.93K | 15.02K | 20.00K | 70.00K | 70.00K | 50.00K |
| Operating Income Ratio | -14.67% | -8.26% | 1.24% | 0.82% | -4.57% | 1.00% | -6.69% | -44.18% | -92.26% | -149.36% | -54.20% | -76.79% | -126.80% | -76.07% | -59.84% | -62.80% | 0.47% | 0.00% | 0.00% | -13.72% | -5.39% | -7.28% | -6.92% | -21.22% | 0.69% | 0.91% | 3.00% | 3.24% | 2.34% |
| Total Other Income/Expenses | 48.00K | -11.00K | -24.00K | 71.00K | -495.00K | -39.00K | -89.00K | -56.00K | -38.00K | 225.00K | -1.13M | -99.00K | 402.00K | 1.44M | 5.00K | -196.00K | 28.94K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.47K | 0.00 | 290.00K | 0.00 | 0.00 |
| Income Before Tax | -7.31M | -5.27M | 583.00K | 409.00K | -1.85M | 231.00K | -1.44M | -6.87M | -10.35M | -13.01M | -7.39M | -6.45M | -8.66M | -3.79M | -2.92M | -2.24M | 35.70K | -170.06K | -144.12K | -246.54K | -107.69K | -145.99K | -147.31K | -468.93K | 33.49K | 20.00K | 360.00K | 70.00K | 50.00K |
| Income Before Tax Ratio | -14.57% | -9.78% | 1.19% | 1.00% | -5.74% | 0.85% | -7.12% | -44.55% | -92.60% | -146.82% | -63.97% | -77.99% | -121.18% | -55.09% | -59.74% | -60.43% | 2.55% | 0.00% | 0.00% | -13.72% | -5.39% | -7.28% | -6.92% | -21.22% | 1.54% | 0.91% | 15.45% | 3.24% | 2.34% |
| Income Tax Expense | -32.00K | 68.00K | 35.00K | 75.00K | 130.00K | 103.00K | 63.00K | 19.00K | 92.00K | 127.00K | 17.00K | 10.00K | -2.00K | 11.00K | 0.00 | 196.00K | 0.00 | 0.00 | 159.60K | 0.00 | 0.00 | 0.00 | 0.00 | 207.95K | -36.49K | 0.00 | 10.00K | -220.00K | 0.00 |
| Net Income | -7.28M | -5.34M | 548.00K | 362.00K | -1.98M | 128.00K | -1.51M | -6.88M | -10.45M | -13.14M | -7.41M | -6.45M | -8.66M | -3.80M | -2.92M | -2.24M | 35.70K | -170.06K | -303.72K | -246.54K | -107.69K | -145.99K | -147.31K | -676.88K | 51.51K | 20.00K | 360.00K | 290.00K | 50.00K |
| Net Income Ratio | -14.51% | -9.90% | 1.12% | 0.88% | -6.15% | 0.47% | -7.44% | -44.67% | -93.42% | -148.26% | -64.12% | -77.99% | -121.15% | -55.25% | -59.74% | -60.43% | 2.55% | 0.00% | 0.00% | -13.72% | -5.39% | -7.28% | -6.92% | -30.62% | 2.37% | 0.91% | 15.45% | 13.43% | 2.34% |
| EPS | -0.54 | -0.39 | 0.04 | 0.03 | -0.17 | 0.01 | -0.14 | -0.64 | -1.20 | -1.51 | -1.33 | -2.17 | -2.22 | -1.35 | -1.04 | -0.81 | -0.12 | -0.10 | -0.22 | -0.22 | -0.15 | -0.21 | -0.21 | -0.95 | 0.01 | 0.03 | 0.49 | 0.39 | 0.07 |
| EPS Diluted | -0.54 | -0.39 | 0.04 | 0.02 | -0.17 | 0.01 | -0.14 | -0.63 | -1.20 | -1.51 | -1.32 | -2.17 | -2.22 | -1.35 | -1.04 | -0.81 | -0.12 | -0.10 | -0.22 | -0.22 | -0.15 | -0.21 | -0.21 | -0.95 | 0.01 | 0.03 | 0.49 | 0.39 | 0.07 |
| Weighted Avg Shares Out | 13.55M | 13.54M | 13.20M | 13.14M | 11.84M | 11.34M | 10.99M | 10.68M | 8.70M | 8.70M | 5.57M | 2.97M | 3.90M | 2.81M | 2.81M | 2.77M | 2.62M | 1.70M | 1.40M | 1.10M | 722.46K | 709.54K | 709.54K | 709.54K | 709.28K | 710.00K | 740.00K | 740.00K | 670.00K |
| Weighted Avg Shares Out (Dil) | 13.55M | 13.54M | 14.16M | 14.57M | 11.84M | 14.10M | 11.00M | 10.98M | 8.70M | 8.70M | 5.61M | 2.97M | 3.90M | 2.81M | 2.81M | 2.77M | 2.62M | 1.70M | 1.40M | 1.10M | 722.46K | 709.54K | 709.54K | 709.54K | 709.28K | 710.00K | 740.00K | 740.00K | 670.00K |
Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024
HACKENSACK, NJ / ACCESSWIRE / December 5, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the second quarter ended October 31,...
Champions Oncology Announces Agreement with Weill Cornell Medicine
HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing...
Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript
Champions Oncology, Inc. (NASDAQ:CSBR ) Q1 2025 Earnings Conference Call September 11, 2024 4:30 PM ET Company Participants Ronnie Morris - Chief Executive Officer David Miller - Chief Financial Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group Operator...
Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million
HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July...
Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024
HACKENSACK, NJ / ACCESSWIRE / September 9, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the first quarter ended July 31,...
Champions Oncology Reports Quarterly Revenue of $14.0 Million
Annual Revenue of $50.2 Million HACKENSACK, NJ / ACCESSWIRE / July 18, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, today announced its financial results for the fiscal year and fourth quarter...
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024
HACKENSACK, NJ / ACCESSWIRE / July 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the fourth quarter and year-ended April...
Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development
HACKENSACK, NJ / ACCESSWIRE / June 4, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, has announced a strategic partnership with Medicines Discovery Catapult (MDC), enhancing their combined capabilities in the expanding...
Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript
Champions Oncology Reports Quarterly Revenue of $12.0 Million
HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its third quarter of fiscal 2024, ended January...
Source: https://incomestatements.info
Category: Stock Reports